BCG May 23, 2024
Key Takeaways
Costs for genomic sequencing have dropped steeply, making new types of genetic tests more accessible and changing the business model for the labs that run them.
- In one possible scenario, lower costs and stricter regulations mean that sequencing becomes commoditized, leading to less innovation and a smaller diagnostics market.
- In another scenario, labs continue to innovate and differentiate themselves, leading to a larger and more vibrant market.
- Labs should plan for both approaches, through simulations that can help them understand how profits will flow.
One segment of advanced diagnostics firms—the next-generation sequencing (NGS) clinical testing labs that run genetic tests—are at an inflection point, based on rapid advances in sequencing technology....
Today's Sponsors
Today's Sponsor